{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T03:44:17Z","timestamp":1726458257263},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.amjcard.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T22:15:15Z","timestamp":1511216115000},"page":"193-198","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study)"],"prefix":"10.1016","volume":"121","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Andrei","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakis","family":"Themistoclakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assen","family":"Goudev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Melino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.10.008_bib0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0015","doi-asserted-by":"crossref","first-page":"16016","DOI":"10.1038\/nrdp.2016.16","article-title":"Atrial fibrillation","volume":"2","author":"Lip","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0030","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.amjcard.2016.01.024","article-title":"Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study)","volume":"117","author":"Gronberg","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/07853890.2016.1267869","article-title":"Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study","volume":"49","author":"Bah","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40256-015-0136-1","article-title":"Outcomes after cardioversion in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants (NOACs): insights from a meta-analysis","volume":"16","author":"Sen","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.amjmed.2016.09.023","article-title":"Antagonist oral anticoagulants for cardioversion in atrial fibrillation: an updated meta-analysis","volume":"130","author":"Renda","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0050","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0055","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2015.02.009","article-title":"A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study","volume":"169","author":"Lip","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2012.10.010","article-title":"Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients","volume":"61","author":"Apostolakis","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0070","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/europace\/euv421","article-title":"Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation","volume":"18","author":"Beyer-Westendorf","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0085","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2008.03059.x","article-title":"Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?","volume":"6","author":"Gallagher","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.10.008_bib0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917316168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917316168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T02:00:49Z","timestamp":1617156049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917316168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0002914917316168"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.10.008","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}